Home Analyst Ratings H.C. Wainwright reiterates Protalix BioTherapeutics Inc. at Buy and assigns price...

H.C. Wainwright reiterates Protalix BioTherapeutics Inc. [PLX] at Buy and assigns price target at $11

H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX]‎ rating to the equivalent of ‎Buy but changed the price target ‎to $11, in a research note dated December 31, 2020. That figure ‎represents around a 212.5% ‎premium ‎from where the company’s shares closed on Wednesday.‎ Other ‎analysts also ‎revised their coverage, with H.C. Wainwright’s analysts reiterating the shares to “a Buy” ‎rating in a ‎research note to investors issued in early June. Meanwhile, Rodman & Renshaw had ‎maintained its ‎rating on PLX to the earlier “Buy” rating, in a research note produced for clients April 17, ‎‎2017. In ‎addition, there was a new coverage from Rodman & Renshaw on April 04, 2016. The research ‎firm ‎rated PLX “a Buy”.

Get the hottest stocks to trade every ‎day before the ‎market opens 100% free. Click here now. ‎‎

Is Protalix ‎BioTherapeutics Inc. [AMEX:PLX] a Good Buy Right Now?

It should be noted that ‎PLX technical ‎indicators for short, intermediate as well as long term progress have placed an overall ‎average of 24% ‎as Sell. The average signal changed from 8% Sell in the last week and compares with ‎‎32% Buy in the ‎past month. Data from Protalix BioTherapeutics Inc.’s Trend Spotter indicated that the ‎signals were ‎Weakening. The stock current average is 0.19 million shares in the past 20 days and the ‎short term ‎average signal indicates a Hold. In the last 50 days, the average trading volume was 0.14 ‎million shares ‎while the medium term average advocated for 50% Sell. The average long-term signal ‎stands at Hold ‎and the 100-day average volume stands at 0.14 million shares.‎‎


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


PLX Price Performance

On ‎Wall Street, Protalix BioTherapeutics Inc. [AMEX:PLX] finished ‎Wednesday’s session up 1.15% at $3.52. ‎The stock went up to $3.76 at the same session while its ‎lowest single day price was $3.45. In the last ‎five days, it saw a rise of about 1.44%, Protalix ‎BioTherapeutics Inc. shares gained by almost 7.32% ‎since the beginning of the year. However, the ‎share price has dropped to as low as -27.65% below its ‎one year high. On 04/29/20, the company ‎shares recorded $4.86, the highest single-day price it has got ‎to in the last 52-weeks and a 52-week low ‎was seen on 03/16/20, the same year at $2.04. The ‎company’s shares have inclined by 7.32% in the ‎past year. The 50-day SMA achieved is $3.54 while the ‎‎200-day SMA is $3.48. Volume gained to 0.57 ‎million from 0.15 million in the previous session.‎‎

PLX ‎Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived ‎around 3.39 level, and in case of violation of this particular level, it will cause more drop to ‎‎3.27 level. ‎On the upper level, 3.89 is still the key resistance. The stock may increase to the subsequent ‎resistance ‎at 3.70. The Relative Strength Index (RSI) pinned on the 14-day chart is 48.35, implying a ‎neutral ‎technical stance while the MACD stands at -0.04, meaning price will decrease in the next ‎trading ‎period. Percent R indicator moved to 64.00%, implying low price movement. Stochastic %K at ‎‎36.00% ‎suggest selling the stock.‎‎

What is the short interest in Protalix BioTherapeutics Inc.?

Short ‎interest in the Protalix ‎BioTherapeutics Inc. stock has plunged, decreasing by -0.15 million shares to ‎total 0.28 million shares ‎on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.13 ‎million, data from Yahoo ‎Finance shows. The increase of 53.66% suggests the stock saw some ‎increased bearish sentiment. The ‎stock’s days to cover (short ratio) moved to while the shorted shares ‎account for just 0.86% of the ‎overall float for the stock.‎‎

Protalix BioTherapeutics Inc.’s Biggest ‎Shareholders: Who Owns Protalix BioTherapeutics Inc. ‎‎[PLX]?

Filings by Highbridge Capital ‎Management LLC showed that the firm now holds a total of ‎‎2,414,487 shares or roughly 7.24% of the ‎outstanding PLX shares. This means their shares have ‎reduced by 0 from the 2,414,487 the investor ‎reportedly held in its prior 13-F filing. With the conclusion ‎of the sale, Renaissance Technologies LLC ‎updated stake is worth $1,760,299. Details in the latest 13F ‎filings reveal that Psagot Mutual Funds Ltd. ‎disposed off their 0.00% stake valued at $1,688,215 while ‎Medical Strategy GmbH cut theirs at ‎‎$1,484,824. ‎‎

PLX Earnings Forecast For The Current Quarter

Protalix BioTherapeutics Inc. ‎‎[PLX] is ‎expected to report weak earnings results for the quarter ending on Dec 2020. Consensus ‎estimates ‎give the company expected revenues of $11.98M and an earnings per share of -$0.08 for ‎Dec 2020. ‎Looking further ahead, the company is expected to report revenue of $16.1M at an EPS of -‎‎$0.02 for ‎Mar 2021. The estimates represent downside of 9.40% and 102.60% in the company’s ‎revenue and ‎earnings per share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

PLX Earnings Estimates For The ‎Current ‎Year

For the financial year, Protalix BioTherapeutics Inc. [AMEX:PLX] is expected to bring ‎in ‎revenue of $55.31M. The returns are nearly $0.62 million higher than the company’s actual ‎revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -0.39, higher ‎than that ‎of FY19 by $0.84. Estimates put this year’s earnings growth at 68.30%, 102.60% for the next, ‎and at an ‎annual 25.00% over the next 5-year period. As for sales, forecasts are for an increase of ‎‎1.10% in the ‎current fiscal year and a further 9.40% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Fulgent Genetics (FLGT) Stock Rocketed 34.46% In Extended Trading Following Strong Financial Results

Shares of the testing services and comprehensive testing solutions technology company Fulgent Genetics, Inc. (NASDAQ: FLGT) rocketed 34.46% in the after-hour trades on Thursday....

Severn Bancorp (SVBI) Stock Is Rising 27% Pre-Market, Thanks To Merger Deal

Severn Bancorp, Inc. (NASDAQ: SVBI) stock is trending upward minutes before start of the regular session today. The stock has been floating at $10.69...

What’s Driving The Lipocine Inc. (LPCN) Stock Higher Pre-Market Today?

Shares of biopharmaceutical company Lipocine Inc. (NASDAQ: LPCN) have been up trending in early hours trading today. As of 07:17 a.m. EST, the stock...

Okta, Inc. (OKTA) Fell 10% In After-Hour Trades. What’s Hurting the Stock?

The stock of Okta, Inc. (NASDAQ: OKTA), a leading independent identity provider, has been dropping 10.46% in pre-market trading today following news of an...

Kiniksa Pharmaceuticals (KNSA) Stock Rose 10% After-Hour, Here’s Why

Shares of biopharmaceutical company Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) rose by 10.34% in extended trading on Wednesday. Changing 54,000 shares of the company in...

Grayscale Adds 175K LTC’s to its Litecoin (LTC) Holdings

The overall sentiments around Litecoin (LTC) are bullish. Litecoin (LTC) has remained in the limelight since the emergence of crypto on the global scale. The...

Severn Bancorp (SVBI) Stock Is Rising 27% Pre-Market, Thanks To Merger Deal

Severn Bancorp, Inc. (NASDAQ: SVBI) stock is trending upward minutes before start of the regular session today. The stock has been floating at $10.69...

Why Soligenix, Inc. (SNGX) Is Surging 16% In Pre-Market Session?

The biopharmaceutical company Soligenix, Inc. (Nasdaq: SNGX) has been surging +18.63% in the pre-market session today. As of 08:55 a.m. EST, the stock was...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.